Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Febe Smits

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Lancet. Haematology|January 2, 2026
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trialCharlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, et al.
Blood|November 22, 2024
Beyond static measurements: dynamic frailty improves survival prediction in multiple myelomaFebe Smits, Kaz Groen, Mark-David Levin, et al.
Blood Advances|August 22, 2025
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trialFebe Smits, Kaz Groen, Mark-David Levin, et al.
Blood|February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapyCharlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Lancet. Haematology|January 2, 2026
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trialCharlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, et al.
Blood|November 22, 2024
Beyond static measurements: dynamic frailty improves survival prediction in multiple myelomaFebe Smits, Kaz Groen, Mark-David Levin, et al.
Blood Advances|August 22, 2025
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trialFebe Smits, Kaz Groen, Mark-David Levin, et al.
Blood|February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapyCharlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Pageof 2